Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) aims to provide a proof-of-principle for a novel strategy for Alzheimer's disease (AD) and AD-related dementias (ADRD) immunotherapies. Specifically, the goal is to examine whether a novel immunotherapeutic approach in cancer immunotherapy with chimeric antigen receptor (CAR) immune cells can be customized as treatments for AD/ADRD.

This NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.